February 4, 2015
ARLINGTON, Va. — HDMA President and CEO John M. Gray released a statement following the House Energy and Commerce Subcommittee on Health’s markup of the Ensuring Patient Access and Effective Drug Enforcement Act of 2015 (H.R. 471), sponsored by Reps. Tom Marino (R-Pa.), Marsha Blackburn (R-Tenn.), Peter Welch (D-Vt.) and Judy Chu (D-Calif.)
“The House Energy and Commerce Subcommittee on Health’s approval of H.R. 471 marks the first step in what HDMA hopes will be a swift journey through the House to final passage. This bill will strengthen the relationship between supply chain stakeholders and regulators and encourage productive dialogue to help mitigate prescription drug abuse and diversion in the U.S. HDMA encourages the House of Representatives to pass this bill quickly, and for the Senate to continue to build on the bipartisan momentum that this bill has achieved to date.”
HDA is the national association representing primary healthcare distributors, the vital link between the nation’s pharmaceutical manufacturers and healthcare providers. Each business day, HDA member companies ensure that over 15 million prescription medicines and healthcare products are delivered safely and efficiently to more than 200,000 pharmacies, hospitals, long-term care facilities, clinics and others nationwide. HDA and its members work daily to provide value and achieve cost savings, an estimated $42 billion each year to our nation’s healthcare system.